DesRosiers Caleb 4

What Happened Caleb DesRosiers, a director of Daxor Corporation (DXR), was granted a derivative award of 2,500 shares (stock options) on June 23, 2026. The award shows an acquisition price of $0.00 (total $0) and is reported as a grant/award rather than a market purchase or sale. The grant is contingent on SEC approval to amend Daxor’s 2020 Incentive Compensation Plan (see footnote F1).

Key Details

• Transaction date: June 23, 2026; Report filed: June 25, 2026 (timely Form 4 filing).
• Award size/pricing: 2,500 derivative awards at $0.00 (reported value $0).
• Vesting: Three installments — 833 shares vest on 6/23/2026, 833 on 6/23/2027, and 834 on 6/23/2028 (footnote F2).
• Contingency: Grant is subject to SEC approval to amend the company’s incentive plan (footnote F1).
• Shares owned after transaction: Not specified in the filing.

Context This filing reports a director grant (transaction code A) of derivative awards (stock options) rather than an open-market buy or sale. Because the grant is contingent on SEC approval of a plan amendment, it is not fully finalized until that approval occurs. Director awards are common as compensation and do not by themselves indicate a buy/sell signal; they simply establish potential future equity exposure subject to vesting and plan terms.